Abstract 776P
Background
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is a treatment strategy recommended for patients with high-grade serous carcinoma (HGSC), who are ineligible for primary debulking surgery (PDS). The presence of the inherently resistant cancer phenotype in the primary tumor is a key factor determining disease progression in such cases.
Methods
We collected the data from 159 NACT-treated patients enrolled in the prospective, longitudinal, multi-region DECIDER study which aims to develop effective means to overcome drug resistance in HGSC. 60 patients with platinum-free interval (PFI) above 6 months and partial/complete response as primary therapy outcome according to the RECIST1.1 criteria were considered as responsive, and 31 patients with PFI below 45 days and progressive/stable disease – as refractory. We integrated multiple types of patient data focusing on the pre-NACT samples, explored potential links between genomic features and patient survival, and specifically employed bulk-RNA sequencing data for hypothesis-generating.
Results
In terms of many different clinical or genomic features, samples derived from chemo-refractory patients resembled chemo-responsive. Homologous recombination (HR)-related mutation signatures and loss of the core HR genes were less frequent in the chemo-refractory patients than in the NACT-patients with at least partial response to the primary therapy. Using PRISM to retrieve the epithelial ovarian carcinoma (EOC)-specific expression profiles and PROGENy to infer pathways activity scores, we found a significantly lower activity (p value = 0.022) of JAK-STAT pathway in the refractory, as compared to the reference group. Further analysis using GSEA supported this conclusion, revealing lower expression levels of transcriptional target genes affected by the Interferon alpha/beta and gamma pathways. Kassandra deconvolution algorithm detected a significantly lower infiltration (p value = 0.026) of CD4 T-cells in the refractory group.
Conclusions
Altogether, these results highlight the importance of the immune component in HGSC primary tumors in the context of intrinsic resistance to NACT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
DECIDER project.
Funding
European Union’s Horizon 2020 research and innovation programme (grant agreement No 965193).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11